Spanish researchers develop open-source tool for cancer gene networks

Researchers at the University of Navarra in Spain have launched RNACOREX, an open-source software that uncovers hidden genetic networks in cancer tumors. The tool analyzes thousands of molecular interactions and predicts patient survival with clarity rivaling advanced AI systems. Tested on data from 13 cancer types, it provides interpretable insights to advance cancer research.

Researchers from the University of Navarra have introduced RNACOREX, a new open-source platform designed to reveal the complex genetic networks underlying cancer. Developed at the Institute of Data Science and Artificial Intelligence (DATAI) in collaboration with the Cancer Center Clínica Universidad de Navarra, the software integrates data from international biological databases with gene expression information to identify key miRNA-mRNA interactions.

These interactions form regulatory networks that influence tumor behavior and patient outcomes. As Rubén Armañanzas, head of the Digital Medicine Laboratory at DATAI and a lead author, explains, "Understanding the architecture of these networks is crucial for detecting, studying, and classifying different tumor types. However, reliably identifying these networks is a challenge due to the vast amount of available data, the presence of many false signals, and the lack of accessible and precise tools capable of distinguishing which molecular interactions are truly associated with each disease."

RNACOREX addresses these issues by building probabilistic models from ranked interactions, offering a clear molecular map of tumor function. Evaluated using data from The Cancer Genome Atlas (TCGA) consortium, the tool was applied to 13 cancer types, including breast, colon, lung, stomach, melanoma, and head and neck tumors. It predicts survival with accuracy comparable to sophisticated AI models but stands out for its interpretable explanations.

Aitor Oviedo-Madrid, first author and a researcher at DATAI, notes, "The software predicted patient survival with accuracy on par with sophisticated AI models, but with something many of those systems lack: clear, interpretable explanations of the molecular interactions behind the results." Beyond predictions, RNACOREX identifies shared molecular patterns across tumors and highlights biomedically relevant molecules, potentially aiding in new hypotheses for diagnostics and treatments. Oviedo-Madrid adds, "Our tool provides a reliable molecular 'map' that helps prioritize new biological targets, speeding up cancer research."

Published in PLOS Computational Biology in 2025 (DOI: 10.1371/journal.pcbi.1013660), RNACOREX is available on GitHub and PyPI, with automated database tools for easy integration. Funded partly by the Government of Navarra's ANDIA 2021 program and ERA PerMed JTC2022 PORTRAIT, the project emphasizes explainable AI in genomics. Armañanzas states, "As artificial intelligence in genomics accelerates, RNACOREX positions itself as an explainable, easy-to-interpret solution and an alternative to 'black-box' models, helping bring omics data into biomedical practice."

Future expansions include pathway analysis and additional molecular layers to better model tumor progression, supporting precision cancer medicine.

ተያያዥ ጽሁፎች

Scientists analyzing a network map of genetic factors in melanoma drug resistance using the PerturbFate platform in a laboratory setting.
በ AI የተሰራ ምስል

PerturbFate maps shared regulatory nodes behind melanoma drug resistance

በAI የተዘገበ በ AI የተሰራ ምስል እውነት ተፈትሸ

Researchers at Rockefeller University report that a new single-cell screening platform, PerturbFate, can trace how many different genetic disruptions converge on common regulatory programs that drive resistance to the melanoma drug vemurafenib, pointing to potential combination-therapy targets.

Spain's National Cancer Research Centre (CNIO) is reviewing whether scientist Mariano Barbacid violated its code of good practices by failing to disclose a conflict of interest in an article retracted by the US National Academy of Sciences. The paper, on a pancreatic cancer therapy tested in mice, was withdrawn because the authors did not declare their shares in Vega Oncotargets, the company set to commercialize the patent. Despite knowing since March, Barbacid did not inform the Cris Cancer Foundation, which raised 3.6 million euros in donations.

በAI የተዘገበ

Scientists from ITQB NOVA and the Portuguese Institute of Oncology have started the BRIDGE project to uncover how aggressive breast cancer evades the immune system. The initiative seeks biomarkers for better prediction of disease progression and personalized treatments. Funded with up to €75,000, the two-year effort uses patient samples to validate lab findings.

Researchers at NYU Langone Health have identified the protein HOXD13 as a key driver of melanoma tumors, promoting blood vessel growth and blocking immune attacks. Disabling HOXD13 in experiments shrank tumors and allowed T cells to infiltrate more effectively. The findings suggest new combination treatments targeting angiogenesis and immune pathways.

በAI የተዘገበ እውነት ተፈትሸ

Researchers at McGill University report a drug-based method to temporarily enhance natural killer (NK) cells—an immune cell type—by inhibiting two proteins, improving the cells’ ability to attack several aggressive cancers in preclinical experiments.

ይህ ድረ-ገጽ ኩኪዎችን ይጠቀማል

የእኛን ጣቢያ ለማሻሻል ለትንታኔ ኩኪዎችን እንጠቀማለን። የእኛን የሚስጥር ፖሊሲ አንብቡ የሚስጥር ፖሊሲ ለተጨማሪ መረጃ።
ውድቅ አድርግ